NOVIGENIX

Novigenix is a Swiss-based company focused on the research, development and commercialization of molecular and immune-based diagnostic tests. Their goal is to detect diseases from the earliest stages, when they are most likely to be responsive to treatment. The company's main product, Colox®, is a blood test designed to predict the risk of colon cancer in patients with certain symptoms, helping doctors to make an informed decision about the need for further, invasive testing.

Novigenix is committed to expanding its portfolio of diagnostic tests to cover other types of cancer and diseases. It leverages advanced technologies in genomics and proteomics, as well as machine learning algorithms, to analyze a patient's blood sample, looking for signals of disease. This approach aims to make disease detection more accurate and less invasive, potentially improving patient outcomes and reducing healthcare costs.